Tag:
business development
Latest Headlines
Latest Headlines
Investor panic could spell tougher times for biotechs
The big message delivered from yesterday's stock market rout was simple: shun risk. Flee to safety. And that kind of investment recipe does not benefit an industry like biotechnology. For biotechs,
PwC: Biotechs must adapt to survive in a harsh new world
Some of the biotech experts at PricewaterhouseCoopers have some harsh news for the drug development industry. In their view the biotech business model is deeply flawed, with the life science upstarts
Red-hot Novavax negotiating vax tech transfers
Back in early April Novavax's stock was trading for a meager 52 cents a share. Before the bell this morning it hit $6.01. And CEO Rahul Singhvi clearly believes that the vaccine-maker, which is
Tech yields forecast, planning upgrades
Five strategies based on industry best practices can help pharma manufacturers improve forecast accuracy and manufacturing planning. So says David Johnston, senior VP at JDA Software, who is
Covance puts campus plans on hold as economy bites
With its profits sliding, the big CRO Covance has put plans for a $145 million campus in Prince William County, VA on hold for up to two years. Welcomed with open arms in 2007 when it came in with
MedImmune, big biotechs plot major 2009 expansion
Biotech companies are being rapidly divided among three distinct classes: growing biotechs worth more than a billion dollars, survivors with money in the bank and a growing segment of downsizing
Report: GSK to fund venture firm, back start-ups
In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from
GPC jettisons 38 workers in new round of layoffs
GPC Biotech's failure to get an FDA approval on satraplatin for cancer will cost the jobs of another
San Diego biotechs expanding ties to China
These days in biotechnology, if you're not already tied in some way to China , you're giving it some
Merck snares NovaCardia in $350M buyout
Merck has bolstered its cardiovascular pipeline with a deal to buy NovaCardia for $350 million in cash. For Merck, the acquisition marks another
